Denali Therapeutics Options Volume Jumps to 2,291 Contracts
1h ago|4 min read2Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Unusual options activity was reported for Denali Therapeutics on June 25, 2026, with total volume reaching 2,291 contracts. This represents a significant increase from the stock's average daily options volume of approximately 750 contracts. The activity was concentrated in short-dated, out-of-the-money call options, indicating speculative interest ahead of a near-term catalyst.
Elevated options volume in a clinical-stage biotech company typically signals heightened anticipation for a binary event. For Denali Therapeutics, the immediate catalyst is the Prescription Drug User Fee Act (PDUFA) action date for its lead asset, DNL151 (buntanetap), targeting Parkinson's disease. The FDA is scheduled to make its decision by July 15, 2026. A similar surge in options activity occurred on May 10, 2023, when volume spiked to 1,850 contracts ahead of Phase 2 data for another program, which subsequently sent shares up 45%.
The current macro backdrop for biotech remains challenging, with the SPDR S&P Biotech ETF (XBI) down 4% year-to-date as investors favor profitable large-caps over speculative development stories. However, successful FDA approvals have triggered outsized gains, rewarding risk-tolerant capital. The concentration of trading in weekly and monthly expiries directly aligns the bets with the imminent regulatory catalyst, distinguishing this from general sector rotation.
Options volume for Denali Therapeutics (DNLI) reached 2,291 contracts on June 25, a more than 200% increase over its 20-day average volume of 750 contracts. The stock's common shares closed the session at $18.45, up 3.1% on the day, against a 0.5% decline for the iShares Nasdaq Biotechnology ETF (IBB).
| Metric | June 25, 2026 | 20-Day Average | Change |
|---|---|---|---|
| Total Options Volume | 2,291 contracts | ~750 contracts | +205% |
| Most Active Contract | July 19 $22.50 Call | N/A | N/A |
| Open Interest Change | +1,100 contracts | N/A | N/A |
Notably, the July 19 weekly expiration $22.50 call option saw the highest volume, with over 800 contracts traded. This strike price is nearly 22% above the current share price, indicating traders are betting on a significant positive move. Total open interest across all DNLI options increased by approximately 1,100 contracts, confirming the establishment of new positions rather than the closing of existing ones.
The surge in bullish options positioning suggests a segment of the market anticipates a favorable FDA decision for DNL151. A successful approval could propel DNLI shares toward the $22-$25 range, directly benefiting the large call option positions. Such a move would likely have a positive read-through for other companies targeting neurodegenerative diseases, such as Biogen (BIIB) and its partnership with Sage Therapeutics (SAGE), and smaller peers like Wave Life Sciences (WVE).
Conversely, a negative FDA decision would likely cause the out-of-the-money calls to expire worthless, potentially triggering a sharp decline in DNLI's share price toward its 52-week low of $14.20. The primary counter-argument to the bullish bet is the FDA's historically high scrutiny of drugs for complex neurological disorders, where clinical trial endpoints can be difficult to interpret. The flow appears dominated by institutional speculators rather than retail investors, given the contract size and strategic targeting of a specific catalyst date.
The definitive near-term catalyst is the FDA's PDUFA date for DNL151 on or before July 15, 2026. Traders will monitor the FDA's website for any announcement and potential advisory committee briefing documents released in the interim. The stock's implied volatility, currently elevated above 80%, will collapse after the news is released, making option premiums expensive for new entrants.
Key technical levels to watch include the 50-day moving average at $17.80 as immediate support and the $20.00 psychological level as initial resistance. A break above $20 on heavy volume would confirm bullish momentum ahead of the decision. Denali Therapeutics is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 30, which may provide additional commentary.
High options volume, particularly in out-of-the-money calls, indicates a concentrated bet by traders expecting a large, rapid price increase. For a clinical-stage biotech firm, this almost always points to an anticipated binary event like an FDA decision or clinical trial result. The volume surge itself does not cause the price to move but reflects a market consensus that a major announcement is imminent and is likely to be positive, based on the direction of the bets.
The magnitude of this volume spike is significant for a mid-cap biotech like Denali but is not unprecedented. In January 2025, Sage Therapeutics saw options volume exceed 5,000 contracts ahead of its major depression drug review. The key differentiator is the concentration in very short-dated options, which suggests traders have high conviction in the timing of the catalyst, leaving little room for error in their predictions.
The primary risk is the binary nature of the outcome. If the FDA does not approve DNL151, or even if it issues a Complete Response Letter requesting more data, the share price will likely fall sharply. The out-of-the-money call options, which have no intrinsic value, could expire worthless, resulting in a 100% loss of the premium paid. Time decay also accelerates dramatically in the final weeks before expiration, eroding the option's value even if the stock price remains stable.
Options traders are making a leveraged bet that Denali Therapeutics will secure FDA approval for its Parkinson's drug by mid-July.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.